Rhode Island Biotechnology Company EpiVax, Inc. Develops Tularemia Vaccine

PROVIDENCE, R.I.--(BUSINESS WIRE)--EpiVax, Inc, a leader in genome-derived vaccines, announced today that it has developed a promising tularemia vaccine candidate (TuliVaxTM) that confers protective immunity. Francisella tularensis is a bacterium considered to be one of the most dangerous potential bioterror agents. This vaccine project was funded by a BioDefense Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). The animal studies, conducted at Rhode Island Hospital, showed that TuliVaxTM protected mice from lethal bacterial challenge.